24 results
Thumbnail

D1.435 - Eosinophilic diseases: from nasal polyposis, eosinophilic asthma to EGPA (Eosinophilic Vasculitis with PolyAngioitis), evaluation of possible biomarkers of disease evolution

Thumbnail

D1.437 - Frequency of SNPs associated with pharmacogenetic phenotypes in Asthma in two Colombian populations

Thumbnail

D1.439 - Is allergic conjunctivitis tip of the allergic iceberg ?

Thumbnail

D1.440 - Single cell pipeline to improve immune cell annotation through comparison of multiple bioinformatic methods

Thumbnail

D3.260 - Bempedoic acid allergy in a patient with hypercholesterolemia

Thumbnail

- D3.262 - Bempedoic acid allergy in a statin-intolerant patient with hypercholesterolemia

Thumbnail

D3.252 - Azithromycin and Mycoplasma pneumonia: an unusual Stevens-Johnson syndrome case

Thumbnail

D3.256 - Is an Early-Type Hypersensitivity Reaction Possible with Both Peroral and Parenteral Anticoagulant Drugs? A Successful 2-Day Peroral Desensitization Protocol to Rivaroxaban

Thumbnail

D3.257 - Two cases of propofol anaphylaxis revealed by provocation test

Thumbnail

D3.258 - Probable drug- induced Enterocolitis Syndrome (DIES) caused by Amoxicillin

Thumbnail

D3.259 - KOLLIPHOR : An excipient to be futher explored

Thumbnail

D3.263 - Rare case of anaphylaxis to lidocaine in skin testing during perioperative anaphylaxis investigation

Thumbnail

D3.264 - Pioneering study evaluating the Basophil Activation Test (BAT), PENFAST and skin sensitization to penicillin in patients with gestational syphilis

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series